Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur Urol. 2009 Oct;56(4):744-5. doi: 10.1016/j.eururo.2009.07.012.

Words of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Author information

1
Department of Urology, Kantonsspital, St. Gallen, Switzerland. hans-peter.schmid@kssg.ch
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center